



**Hyatt Regency  
Houston/Galleria**  
2626 Sage Road  
Houston, Texas 77056  
Phone: (832) 803-1234

Jointly provided by:



# Update on Treatment Options for Leukemia: Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia and Chronic Myelogenous Leukemia

**Saturday, November 4, 2017**  
7:00 AM - 3:40 PM

## Program Chairs

### Jorge Cortes, MD

Professor and Chair, Department of Leukemia,  
Division of Cancer Medicine,  
The University of Texas M D Anderson Cancer Center,  
Houston, TX

### Elias Jabbour, MD

Associate Professor, Department of Leukemia  
Division of Cancer Medicine,  
The University of Texas MD Anderson Cancer Center,  
Houston, TX

## Educational Grants

Amgen Inc.; Janssen Scientific Affairs, LLC;  
Novartis Pharmaceuticals Corporation;  
Gilead Sciences Inc.; Takeda Oncology; Pfizer

## REGISTRATION FORM

Update on Treatment Options for Leukemia: Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia and Chronic Myelogenous Leukemia

First Name \_\_\_\_\_ Middle Initial \_\_\_\_\_ Last Name \_\_\_\_\_

Physician  Pa-C  NP  PhD  Pharmacist  Industry  Nurse  Other

Mailing Address \_\_\_\_\_

City \_\_\_\_\_ State \_\_\_\_\_ Zip Code \_\_\_\_\_

Phone \_\_\_\_\_ Fax \_\_\_\_\_

Email \_\_\_\_\_

Specialty \_\_\_\_\_

Fax registration to: 443-267-0016  
Mail registration to:  
860 Hebron Pkwy, Suite 1104  
Lewisville, TX 75057  
 Check box to receive information  
about Live and Webcast programs.  
You can unsubscribe at any time.

## Registration Fee (Registration fee partially covers buffet breakfast, lunch and syllabus book)

	Early Registration Fee - Up to 10/23/17	Discounted Registration Fee - 10/24/17 - 10/30/17	Regular Registration Fee - 10/31/17 - 11/4/17
<input type="checkbox"/> Physicians	\$100.00	\$130.00	\$160.00
<input type="checkbox"/> Nurses, Nurse Practitioners, Physician Assistants	\$75.00	\$95.00	\$115.00
<input type="checkbox"/> Pharmacists, Fellows	\$75.00	\$95.00	\$115.00
<input type="checkbox"/> Industry †	\$350.00	\$400.00	\$450.00

† Person(s) employed by for-profit organizations such as pharmaceutical and biotech companies, and financial institutions

**No refund. Substitution is allowed.**

Payment may be made:  MC  Visa  Discover  Check

Credit Card Number \_\_\_\_\_ Expiration Date \_\_\_\_\_

Name and address (as given on the monthly credit card statement) \_\_\_\_\_

Pharmacist e-profile NABP#: \_\_\_\_\_ Pharmacist DOB (MMDD): \_\_\_\_\_

Signature \_\_\_\_\_

Register online at [www.cancernetus.com](http://www.cancernetus.com)  
Please make checks payable to **CancerNet, LLC**. Mail checks to CancerNet, LLC, 860 Hebron Pkwy, Suite 1104, Lewisville, TX 75057

To reserve your place for the meeting, please complete the registration form and fax it to 443-267-0016. For questions, please call Brian Waggoner at 972-459-5222 or E-mail: [brianw@cancernetus.com](mailto:brianw@cancernetus.com)

## Faculty

### Jorge Cortes, MD

Professor and Chair, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center Houston, TX

### Alessandra Ferrajoli, MD

Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center Houston, TX

### Guillermo Garcia-Manero, MD

Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center Houston, TX

### Elias Jabbour, MD

Associate Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

### Tapan M. Kadia, MD

Associate Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

### Farhad Ravandi, MD

Professor and Chief, Section of Developmental Therapeutics, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

## Update on Treatment Options for Leukemia: Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia and Chronic Myelogenous Leukemia

**Saturday, November 4, 2017**

**Hyatt Regency Houston/Galleria**

2626 Sage Road, Houston, Texas 77056

Phone: (832) 803-1234

### Statement of Need / Program Overview

This symposium is intended to improve care of patients with acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML) and chronic myelogenous leukemia (CML) by accelerating adoption of new guidelines and evidence-based practice change. The format will include didactic lectures from known opinion leaders, question and answer sessions, and ample opportunity for participant interaction with faculty.

### Target Audience

This symposium is directed primarily to hematologists/oncologists, physician assistants, nurse practitioners, registered nurses, pharmacists and fellows in training interested in new development in ALL, CLL, AML and CML. No specific skill or knowledge other than a basic training in hematology/oncology is required for successful participation in this activity.

### Learning Objectives

- Outline the alterations in cytogenetic, molecular abnormalities, NOTCH1, CRLF2 mutations, epigenetic markers in the diagnosis and treatment of patients with acute lymphoblastic leukemia (ALL)
- Select the novel therapeutic options for adolescents and young adults (AYA) relapsed/refractory Philadelphia-positive and Philadelphia-negative patients with ALL
- Assess the prognostic markers, risk stratification and their impact on clinical practice of patients with chronic lymphocytic lymphoma (CLL)
- Identify and apply individualized treatment strategies based on current and emerging novel therapies for CLL
- Describe the alterations in driver mutations revealing molecular subgroups leading to disease classification and prognostic stratification in acute myeloid leukemia (AML)
- Recognize how compound genotypes are related to clinical outcomes in AML patients treated with novel agents
- Evaluate the first line therapy options for chronic myelogenous leukemia (CML) in chronic phase
- Identify response assessment and management of tyrosine kinase inhibitors resistance in the treatment of CML
- Cite treatment options for myelodysplastic syndromes

## Agenda

# Update on Treatment Options for Leukemia: Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia and Chronic Myelogenous Leukemia

7:00 AM Breakfast Buffet and Registrations

8:25 AM Welcome and Introductions

Jorge Cortes, MD/ Elias Jabbour, MD

## ACUTE LYMPHOBLASTIC LEUKEMIA

8:30 AM Overview of Diagnosis Based on Cytogenetic, Molecular Abnormalities, NOTCH1, CRLF2 Mutations, Epigenetic Changes in Patients with Acute Lymphoblastic Leukemia (ALL)

Jorge Cortes, MD

9:00 AM Novel Therapies for Adolescents and Young Adults (AYA), Philadelphia-positive and Philadelphia-negative Relapsed/Refractory Patients with ALL

Elias Jabbour, MD

9:30 AM Panel Discussion and Case Presentation

Jorge Cortes, MD / Elias Jabbour, MD

9:50 AM Break

## CHRONIC LYMPHOCYTIC LEUKEMIA

10:05 AM Role of Emerging Prognostic Makers and Risk Stratification in Treatment Decision Making for Patients with Chronic Lymphocytic Leukemia (CLL)

TBD

10:35 AM Changing the Treatment Paradigm for CLL: Chemoimmunotherapy versus Targeted Therapy

Alessandra Ferrajoli, MD

11:05 AM Panel Discussion and Case Presentation

TBD / Alessandra Ferrajoli, MD

## ACUTE MYELOID LEUKEMIA

11:25 AM Overview of Alterations in Driver Mutations Revealing Molecular Subgroups Leading to Disease Classification and Prognostic Stratification in Acute Myeloid Leukemia (AML)

F. Ravandi-Kashani, MD

12:00 PM Lunch Buffet

12:45 PM Compound Genotype Based Novel Therapies and Clinical Outcomes in Patients with AML

Tapan Kadia, MD

1:15 PM Panel Discussion and Case Presentation

F. Ravandi-Kashani, MD / Tapan Kadia, MD

## CHRONIC MYELOGENOUS LEUKEMIA

1:35 PM Overview of First Line Therapy of Chronic Myelogenous Leukemia (CML) in Chronic Phase

Jorge Cortes, MD

2:05 PM Response Assessment and Management of Tyrosine Kinase Inhibitor Resistance in the Management of CML

Elias Jabbour, MD

2:35 PM Break

2:50 PM Overview of Treatment Options for Myelodysplastic Syndromes

Guillermo Garcia-Manero, MD

3:20 PM Panel Discussion and Case Presentation


Jorge Cortes, MD / Elias Jabbour, MD / G. Garcia-Manero, MD

3:40 PM Closing Remarks and Adjourn

Jorge Cortes, MD/ Elias Jabbour, MD

## Physician Continuing Education

### Accreditation Statement:


 This activity has been planned and implemented in accordance with the accreditation requirements and the policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of A. Webb Roberts Center for Continuing Medical Education of Baylor Scott & White Health and CancerNet, LLC. The A. Webb Roberts Center for Continuing Medical Education of Baylor Scott & White Health is accredited by the ACCME to provide continuing medical education for physicians.

### Credit Designation:

The A. Webb Roberts Center for Continuing Medical Education of Baylor Scott & White Health designates this educational activity for a maximum of 6.0 AMA PRA Category 1 Credit(s)<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


## Nursing Continuing Education

### Accreditation Statement:

 Amedco is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. This course is co-provided by Amedco and CancerNet, LLC. Total of 6.0 contact hours.

## Pharmacist Continuing Education

### Accreditation Statement:

 This program is co-sponsored by Amedco and CancerNet, LLC. Amedco is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

### Credit Designation:

Successful completion of this program qualifies for 6.0 knowledge-based contact hours. UAN: 0453-9999-17-448-L04-P.

Instructions for Claiming AMA PRA Category 1 Credit(s) (Physicians, PAs and NPs):

- In order to receive credit, all attendees must sign-in at the beginning of the activity, submit a completed evaluation and claim credit online through <http://cme.sw.org>. Instructions on how to complete the evaluation and claiming credit online are included in program handouts.

### Participant Requirements for Credit (Nurses and Pharmacists):

- Participants must fully attend all sessions as well as turn in a completed signature verification form (No partial credit will be given). Participants can earn Continuing Education credits for this program by electronically logging onto the website for;

- ♦ Nurses and Pharmacists at <http://can.cmecertificateonline.com> and completing the evaluation. After completion of the evaluation, you can print your certificate immediately and one is emailed to you. Pharmacists must complete the evaluation by December 15, 2017. Only Statements of Credit issued from CPE Monitor are valid in the US.

- All participant names will be checked against program attendance sheets for verification of attendance.

**Disclosure & Evaluation:** All participants will have the opportunity to evaluate the educational session and presenter as well as the ability to identify their future educational needs. Disclosure will be made on the day of the program regarding any relevant financial relationship an individual may have with a commercial interest organization.

Participants may reserve guest rooms by calling (832) 803-1234



860 Hebron Pkwy, Suite 1104, Lewisville, TX 75057  
Tel: (972) 459-5222 • Fax: (443) 267-0016  
[www.cancernetus.com](http://www.cancernetus.com)